Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 17/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.81 |
| ▸ | CDK1 | P06493 | 7/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27382932 | 0.99 | CDK2 (0.83) | CDK2KCNH2CDK1 | |
| SCHEMBL30828143 | 0.99 | CDK2 (0.83) | CDK2KCNH2CDK1 | |
| SCHEMBL3937054 | 0.90 | CDK2 (0.79) | CDK2KCNH2CDK1 | |
| SCHEMBL13522737 | 0.90 | CDK2 (0.85) | CDK2KCNH2CDK1 | |
| SCHEMBL4516013 | 0.90 | KCNH2 (1.00) | CDK2KCNH2CDK1 | |
| SCHEMBL4524256 | 0.90 | CDK2 (1.00) | CDK2KCNH2CDK1 | |
| Hydrochloric Acid SCHEMBL1156127 | 0.89 | CDK2 (0.77) | CDK2KCNH2CDK1 | |
| Lithium Ion SCHEMBL1447528 | 0.89 | CDK2 (0.80) | CDK2KCNH2CDK1 | |
| SCHEMBL12861898 | 0.87 | CDK2 (0.77) | CDK2KCNH2CDK1 | |
| SCHEMBL2924704 | 0.87 | KCNH2 (0.82) | CDK2KCNH2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | disclosed |
| EP-2044058-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| US-20100240686-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-23 | — | — | US | disclosed |
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-2044058-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
| WO-2007148070-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | CDK2 4/4885KCNH2 3837/4885CDK1 6/4885 |
| US-20100240686-A1 | CHEMICAL COMPOUNDS | CCNI, CDKN1A, CCNB1 | CDK2 11/4885KCNH2 2925/4885CDK1 12/4885 |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | CDK2 13/4885KCNH2 4262/4885CDK1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.